

Research paper

Synthesis, antileishmanial activity and mechanism of action studies of novel β -carboline-1,3,5-triazine hybrids

Paula Baréa^a, Valéria Aquilino Barbosa^a, Danielle Lazarin Bidóia^b,
Jéssica Carreira de Paula^b, Talitha Fernandes Stefanello^b, Willian Ferreira da Costa^a,
Celso Vataru Nakamura^b, Maria Helena Sarrajiotto^{a,*}

^a Universidade Estadual de Maringá (UEM), Departamento de Química, Av. Colombo, 5790, CEP: 87020-900, Maringá, PR, Brazil

^b Universidade Estadual de Maringá (UEM), Departamento de Análises Clínicas, Universidade Estadual de Maringá, Av. Colombo, 5790, CEP: 87020-900, Maringá, PR, Brazil

ARTICLE INFO

Article history:

Received 29 December 2017

Received in revised form

15 February 2018

Accepted 2 March 2018

Available online 6 March 2018

Keywords:

β -carboline

1,3,5-Triazine

Antileishmanial

Leishmania amazonensis

Cell death mechanism

ABSTRACT

A series of novel hybrids β -carboline-1,3,5-triazine were synthesized and evaluated for their *in vitro* antileishmanial activity against promastigote and amastigote forms of *Leishmania amazonensis*. Among the compounds tested, the hybrids **9d**, **9e**, **16a** and **16b** showed potent activity against the promastigote forms with IC₅₀ values less than 8 μ M. Compounds **9e** and **16b** were also active against amastigote forms, displaying IC₅₀ values of $1.0 \pm 0.1 \mu$ M and $1.2 \pm 0.5 \mu$ M, respectively. Besides that, the hybrid **16b** bearing the 4-methoxyphenyl group at C-1 of β -carboline and isopropylamino group at 1,3,5-triazine, showed low toxicity, being 23.5 and 121.4 times more toxic for promastigotes and axenic amastigotes, respectively, than for macrophage J774-A1 cell lines. Investigation of action mechanism in promastigotes showed that compound **16b** caused alterations in cell division cycle and an increase of lipid-storage bodies, leading the cells to death through various factors. The accumulation of lipid bodies may be associated with apoptotic cell death.

© 2018 Elsevier Masson SAS. All rights reserved.

1. Introduction

Leishmaniasis is considered a neglected disease, and it is caused by protozoan parasites of the genus *Leishmania*. According to World Health Organization (WHO), leishmaniasis is endemic in 97 countries and territories, affecting mainly people in Africa, Asia and Latin American [1]. *Leishmania* infections are manifested in three clinical different forms: visceral (VL), cutaneous (CL) and mucocutaneous [1]. In South America, the species *L. amazonensis* is one of the etiological agents of cutaneous leishmaniasis, which may progress to diffuse cutaneous leishmaniasis in immunosuppressed individuals [2]. Current chemotherapies for leishmaniasis include treatment with pentavalent antimonials as first-line drugs, and amphotericin B, pentamidine, paromomycin, and miltefosine as second-line drugs [3]. However, the current drugs used clinically exhibit high toxicity, resistance, various side effects, and an increased incidence of treatment failure [2–5]. Beside this, no

vaccines against *Leishmania* infections are available [6]. Therefore, there is a significant need to develop new more effective and less toxic antileishmanial agents.

In this context, several classes of compounds [7], including natural and synthetic β -carboline alkaloids [8–16], were described as potential antileishmanial agents.

In our previous work we have demonstrated that β -carbolines containing substituents at 1- and 3-positions of β -carboline nucleus have shown potent antileishmanial activity [17–22]. For instance, Tonin et al. [19] and Pedroso et al. [20] demonstrated the potentiality of *N*-alkyl-(1-phenylsubstituted- β -carboline)-3-carboxamides as antileishmanial agents. The compound *N*-butyl-1-(4-methoxy)-phenyl- β -carboline-3-carboxamide (**I**, Fig. 1), for example, showed IC₅₀ of 0.25 μ M against *L. amazonensis* promastigotes, displaying a selectivity index ratio (SI) 2084 times higher for the parasite than for macrophages J774G8 cells. Further studies showed that this compound was also active against axenic and intracellular amastigote forms of *L. amazonensis*, exhibiting high selectivity for the parasite. Studies on mechanism of action demonstrated that compound **I** exerts its antileishmanial activity through a cytostatic effect, thus preventing cellular proliferation [21]. In the same way,

* Corresponding author.

E-mail address: mhsarrajiotto@uem.br (M.H. Sarrajiotto).




Fig. 1. Structures of β -carboline and 1,3,5-triazine derivatives with antileishmanial activity and of β -carboline-1,3,5-triazine hybrids proposed.

the analog containing the *N*-benzyl instead *N*-butyl group was active against promastigote and axenic amastigote forms with IC_{50} of 2.6 and 1.0 μM , respectively, and killed *L. amazonensis* promastigotes through different cell death pathways, including apoptosis and autophagy [20,22].

Additionally, compounds having a 1,3,5-triazine motif possess a broad range of biological activities, which makes this heterocycle an important scaffold in the search and development of new drugs [23]. The potentiality of 1,3,5-triazine derivatives as antileishmanial agents has been demonstrated in several studies [24–28]. Studies on structure-activity relationship have pointed that the presence of appropriated substituents at 2-, 4- and 6-positions of the 1,3,5-triazine nucleus can enhance the antileishmanial activity. For instance, the 1,2,4-triazino [5,6-*b*]indol-3-ylthio-1,3,5-triazines derivatives (**II**, Fig. 1) containing *N*-ethylpiperazine, isopropylamino and tertbutylamino substituents in 1,3,5-triazine nucleus showed more than 90% inhibition against promastigotes form of *L. donovani* while compounds with the *N*-methylpiperazine and morpholine substituents showed no inhibition or less than 50% of inhibition [27]. Also, the importance of the chain length between the triazine units of triazine mimetic **III** (Fig. 1) was demonstrated by Chauhan et al. [28]; the dimer with 5-aminopentan-1-ol linker was found to be inactive while the dimer with 4-aminobutan-1-ol linker exhibited potent antiamastigote activity for *L. donovani*. This compound also showed significant *in vivo* inhibition (74.41%) in *L. donovani*/hamster model, and prevent the progression of leishmania parasite. Besides this, it was demonstrated that the incorporation of 1,3,5-triazine ring, bearing different amino groups, into β -carboline nucleus led to compounds (**IV**, Fig. 1) with significant *in vivo* inhibition of *L. donovani* amastigotes [14].

The inefficacy and high toxicity of the drugs used to treat leishmaniasis infection, and the antileishmanial properties of both β -carboline and 1,3,5-triazine nucleus, motivated us to synthesize β -carboline-1,3,5-triazine hybrids (**V**, Fig. 1) in order to obtain new compounds with potent antileishmanial activity and low toxicity. The novel hybrids were evaluated against promastigote and

amastigote forms of *L. amazonensis* and their cytotoxicity were determined. Also, studies on the antileishmanial mechanism of action were carried out for the most active derivative synthesized.

2. Results and discussion


2.1. Chemistry

The novel designed β -carboline-1,3,5-triazine hybrids were synthesized by reaction of appropriate β -carboline intermediates with cyanuric chloride, a commercially useful reagent due the reactivity of its chlorine atoms toward nucleophiles [29], according the synthetic routes illustrated in Schemes 1 and 2. The hybrids **8a-d**, **9a-e** and **10a**, bearing a phenyl substituted group at 1-position of β -carboline nucleus and chlorine atoms at 6- and 4-positions of 1,3,5-triazine ring, were obtained from the intermediates **5a-d**, **6a-e** and **7a**, respectively (Scheme 1). These intermediates were prepared by a Pictet-Spengler condensation of the *L*-tryptophan methyl ester (**2**) with benzaldehyde (**a**), 4-methoxybenzaldehyde (**b**), 4-fluorobenzaldehyde (**c**), 2-chlorobenzaldehyde (**d**) and 3-nitrobenzaldehyde (**e**) followed by oxidation of the *cis/trans* mixture of **3a-e** in the presence of sulfur, in refluxing xylene, which afforded the derivatives **4a-e** [17–22]. Reaction of the methyl β -carboline-3-carboxylates (**4**) with hydrazine hydrate, ethylenediamine and hexamethylenediamine afforded the corresponding β -carboline-3-carboxamides **5a-e**, **6a-e** and **7a**. Treatment of **5a-d**, **6a-d** and **7a** with a suspension of cyanuric chloride in a mixture of water: acetonitrile 1:1, at 0 °C, followed by addition of sodium hydroxide in THF, gave the compounds **8a-d**, **9a-d** and **10a**, respectively, in good yields (45–98%). The hybrid **9e** was prepared from the reaction the intermediate **6e** with cyanuric chloride, at 0 °C, using K_2CO_3 as basis and tetrahydrofuran as solvent. The intermediate **5e** was also submitted to reaction with cyanuric chloride, under the same conditions; however, in this case was observed the formation of a complex mixture of products.

In order to evaluate the effect of other substituents than chlorine into 1,3,5-triazine portion on antileishmanial activity, we synthesized the β -carboline-1,3,5-triazine hybrids **11a-16a**, bearing different amino substituents in the 4- and 6-positions of 1,3,5-triazine ring (Scheme 2). For this, the intermediate **6a** ($n = 2$) was subjected to reaction with cyanuric chloride, at 0 °C for 1 h, using NaOH as basis and water-acetonitrile and THF as solvent, followed by addition to the reaction mixture, without previous treatment, of 10 equivalents of an appropriate amine. Heating of the reaction mixture at 70 °C for 48 h afforded the compounds **11a-16a** (Scheme 2).


The antileishmanial activity results for **11a-16a** (Table 1) showed that the hybrid **16a**, bearing the isopropylamino group at 1,3,5-triazine ring, was the only one active compound of this series. Therefore, compounds **16b-d** ($n = 2$) and **17a-d** ($n = 0$), containing the isopropylamino group at 1,3,5-triazine unity and the phenyl substituted group at position-1 of the β -carboline nucleus, were synthesized from the reaction of the respective intermediates **6b-d** and **5a-d** with cyanuric chloride in basic medium, followed by addition of 10 equivalents of isopropylamine (Scheme 2). The reaction of **6e** with cyanuric chloride in the presence of K_2CO_3 and excess isopropylamine afforded the compound **16e** in 40% yield.

All hybrids were characterized by their spectral data (HRMS, 1H NMR and ^{13}C). The characterization of the β -carboline-1,3,5-triazine hybrids **8a-d**, **9a-e** and **10a** bearing chlorine at 6- and 4-positions of 1,3,5-triazine ring was mainly supported by the signals at δ_C 167.1–170.3 (C_0), characteristic of C-Cl bonds, and at δ_C 163.9–165.3 (C_0) related to C-2 of the 1,3,5-triazine ring, in ^{13}C NMR spectra. The hybrids **11a-16a**, **16b-e** and **17a-d** were characterized by the signal of aminoalkyl substituents linked to 6- and 4-



$R^1 =$ a) H; b) 4-OCH₃; c) 4-F; d) 2-Cl; e) 3-NO₂;

Scheme 1. Synthesis of compounds **8a-d**, **9a-e** and **10a**. Reagents and conditions: (a) MeOH, H₂SO₄ (cat.), reflux, 48 h; (b) R¹Ph-CHO, CH₂Cl₂, TFA, rt, 48 h; (c) Sulfur, xylene, reflux, 48 h; (d) Hydrazine hydrate, EtOH, reflux, 48 h; (e) Ethylenediamine, rt, 24 h; (f) Hexamethylenediamine, MeOH, CHCl₃, reflux, 36 h; (g) i) Cyanuric chloride/H₂O: CH₃CN 1:1, NaOH (1 M)/THF, 0 °C, 1 h for **8a-d** and **9a-d**; ii) Cyanuric chloride, K₂CO₃, THF, 0 °C, 1 h for **9e**.



Comp.	R ¹	R ²	Comp.	R ¹	R ²
11a	Ph	H ₂ NNH	16a; 17a	Ph	
12a	Ph		16b; 17b	4-OCH ₃ -Ph	
13a	Ph		16c; 17c	4-F-Ph	
14a	Ph	H ₃ C-N	16d; 17d	2-Cl-Ph	
15a	Ph		16e^a	3-NO ₂ -Ph	

^aFor **16e** was used K₂CO₃ as basis and THF as solvent


Scheme 2: Synthesis of compounds **11a-16a**, **16b-e** and **17a-d**.

Scheme 2. Synthesis of compounds **11a-16a**, **16b-e** and **17a-d**.

positions of 1,3,5-triazine. For example, the compounds containing the isopropylamino substituent (**16a-e** and **17a-d**) showed the presence of signals at δ_H 0.86–1.12 (12H, CH₃), δ_H 4.01–4.09 (2H,

CH), in ¹H NMR spectra, and δ_C 22.5–22.7 (CH₃) and δ_C 40.1–41.6 (CH), in ¹³C NMR spectra, related to methylene hydrogens and carbons, respectively.

Table 1
Antileishmanial activity data for compounds **8a-d**, **9a-e**, **11a-15a**, **16a-e** and **17a-d** against *L. amazonensis*.



Comp.	n	R ¹	R ²	Promastigotes	Amastigotes	J774A1	SI	
				IC ₅₀ (μM)	IC ₅₀ (μM)	CC ₅₀ (μM)	PRO	AMA
8a	0	Ph	Cl	43.3 ± 10.3	1.1 ± 0.1	94.5 ± 7.8	2.2	85.9
8b	0	4-OCH ₃ -Ph	Cl	>100	n.t	n.t	n.d	n.d
8c	0	4-F-Ph	Cl	>100	n.t	n.t	n.d	n.d
8d	0	2-Cl-Ph	Cl	34.1 ± 10.6	n.t	22.0 ± 4.2	0.6	n.d
9a	2	Ph	Cl	30.9 ± 0.9	1.9 ± 0.4	134.6 ± 11.8	4.4	70.8
9b	2	4-OCH ₃ -Ph	Cl	67.5 ± 0.1	1.0 ± 0.1	201.3 ± 3.9	3.0	201.3
9c	2	4-F-Ph	Cl	>100	n.t	n.t	n.d	n.d
9d	2	2-Cl-Ph	Cl	7.6 ± 2.02	n.t	28.5 ± 3.6	3.8	n.d
9e	2	3-NO ₂ -Ph	Cl	5.1 ± 0.1	1.1 ± 0.2	83.1 ± 7.8	16.3	75.5
10a	6	Ph	Cl	>100	n.t	n.t	n.d	n.d
11a	2	Ph	-NHNH ₂	>100	n.t	n.t	n.d	n.d
12a	2	Ph		>100	n.t	n.t	n.d	n.d
13a	2	Ph		>100	n.t	n.t	n.d	n.d
14a	2	Ph		>100	n.t	n.t	n.d	n.d
15a	2	Ph		>100	n.t	n.t	n.d	n.d
16a	2	Ph		7.5 ± 2.5	35.0 ± 0.5	98.1 ± 6.5	13.1	2.80
16b	2	4-OCH ₃ -Ph		6.2 ± 1.4	1.2 ± 0.5	145.7 ± 10.1	23.5	121.4
16c	2	4-F-Ph		>100	n.t	n.t	n.d	n.d
16d	2	2-Cl-Ph		>100	n.t	n.t	n.d	n.d
16e	2	3-NO ₂ -Ph		44.6 ± 1.2	n.t	86.3 ± 11.8	1.9	n.d
17a	0	Ph		39.7 ± 2.9	32.5 ± 3.4	102.7 ± 9.9	2.6	3.16
17b	0	4-OCH ₃ -Ph		>100	n.t	n.t	n.d	n.d
17c	0	4-F-Ph		43.4 ± 1.2	n.t	50.0 ± 14.1	1.2	n.d
17d	0	2-Cl-Ph		>100	n.t	n.t	n.d	n.d
Miltefosine ^a	—	—	—	18.5 ± 1.1	2.4 ± 0.1	40.5 ± 1.7	2.2	16.9

^a Positive control; n.t: not tested; n.d: not determined.

2.2. Antileishmanial activity

In this work, novel β -carboline-1,3,5-triazine hybrids synthesized (**8a-d**, **9a-e**, **10a-15a**, **16a-e** and **17a-d**) were evaluated *in vitro* against the promastigote and amastigote forms of *L. amazonensis*. The antileishmanial assay results are shown in Table 1. The compounds that showed IC₅₀ (50% Inhibitory Concentration) values greater than 100 μ M were considered inactive. The toxic effects on the host cells were determined by the selectivity index (SI). The SI for each active compound was calculated as the ratio between the cytotoxicity (CC₅₀) for the macrophage J774-A1 cell lines and IC₅₀ against the promastigote and amastigote forms of *L. amazonensis*.

In order to evaluate the influence of the linkers between the β -carboline and 1,3,5-triazine units, firstly, the β -carboline-1,3,5-triazine hybrids **8a** (n = 0), **9a** (n = 2) and **10a** (n = 6), bearing the phenyl group at 1-position of β -carboline nucleus and chlorine atoms at 4- and 6-positions of triazine ring, were assayed for their antileishmanial activity. As showed in Table 1, compounds **8a** (n = 0) and **9a** (n = 2) were moderately active for *L. amazonensis* promastigotes, with C₅₀ values of 43.3 μ M and 30.9 μ M, respectively, while the compound **10a** (n = 6) was inactive. The hybrids **8a** and **9a** showed also potent activity and high selectivity against amastigote forms of *L. amazonensis*, with IC₅₀ values minor than 2 μ M and SI of 85.9 and 70.8, respectively.

Aiming to increase the activity of compounds **8a** and **9a** against *L. amazonensis* promastigotes we introduced electron-donating and electron-withdrawing groups at the phenyl group in the 1-position of the β -carboline nucleus. The 4-methoxy, 2-chloro and 3-nitro substituents were chosen based on our previous studies, which demonstrated that these groups at 1-phenyl provided β -carboline derivatives with promising antileishmanial activities [19–21]. Besides that, a new withdrawing substituent (4-fluoro) was chosen in order to compare its effects on the antileishmanial activity with those of the other groups.

In this work, the introduction of 4-methoxy (**8b** and **9b**) and 4-fluoro (**8c** and **9c**) at 1-phenyl group led to a decrease or loss of activity against promastigote forms in comparison to **8a** and **9a**. On the other hand, the presence of 2-chloro and 3-nitro substituents at 1-phenyl group in **9d** and **9e** resulted in a 4- and 6-fold increase, respectively, in the activity towards promastigotes. The hybrids **9b** and **9e**, as well as **9a** presented potent activity and high selectivity index for the amastigote forms.

From the IC_{50} data for the β -carboline-1,3,5-triazine derivatives **11a–16a** we verified that only the compound **16a**, with the isopropylamino group in 1,3,5-triazine ring, was active, showing IC_{50} values of $7.5 \pm 2.5 \mu M$ and $35.0 \pm 0.5 \mu M$, respectively, against promastigotes and amastigotes forms of *L. amazonensis*. Comparison of these results with those obtained for **9a** show that replacement of the chlorine atoms at C-4 and C-6 of 1,3,5-triazine ring by isopropylamino group increases about 4-fold the activity to the promastigotes form. On the other hand, the insertion of isopropylamino group in **16a** resulted in a decrease of activity for the amastigote forms by approximately 18 times in comparison with those of **9a**. The introduction of the others amino substituents in 1,3,5-triazine ring (**11a–15a**) also led to loss of activity for promastigote forms.

Finally, we evaluated the antileishmanial activity for the hybrids bearing the isopropylamino group at C-4 and C-6 of 1,3,5-triazine and the phenyl substituted groups at the β -carboline nucleus **16b–e** ($n = 2$) and **17a–d** ($n = 0$).

Analysis of IC_{50} data for the series where $n = 2$ showed that the insertion of the isopropylamino group led to a loss and decrease of the activity towards the promastigotes for compounds **16d** ($IC_{50} > 100 \mu M$) and **16e** ($IC_{50} = 44.6 \pm 1.2 \mu M$) compared to **9d** ($IC_{50} = 7.6 \pm 2.02 \mu M$) and **9e** ($IC_{50} = 5.1 \pm 0.1 \mu M$), respectively. On the other hand, the replacement of chlorine atoms of **9b** ($IC_{50} = 67.5 \pm 0.0 \mu M$) by isopropylamino group in compound **16b** ($IC_{50} = 6.2 \pm 1.4 \mu M$) increased the antileishmanial activity against to the promastigote forms by about 10 times. Compound **16b** was also active for amastigotes ($IC_{50} = 1.2 \pm 0.5 \mu M$), with increase of the activity by about 30-fold when compared with the compound **16a** ($IC_{50} = 35.0 \pm 0.5 \mu M$). Besides that, the hybrid **16b** showed a decreasing toxicity, being 23.5 and 121.4 times more toxic for promastigotes and axenic amastigotes of the parasites, respectively, than for the host cells (Table 1). The positive control miltefosine, a drug used for treatment of cutaneous leishmaniasis [30], showed IC_{50} of 18.5 and $2.4 \mu M$, and SI of 2.2 and 16.9, for promastigotes and amastigotes, respectively (Table 1). Thus, **16b** becomes promising for other studies.

Compounds **17a–d** ($n = 0$) were moderately active or inactive against *L. amazonensis* promastigotes, showing that the best linker between the β -carboline and 1,3,5-triazine moieties is those having the ethylene unity ($n = 2$).

2.3. Transmission electron microscopy

As the compound **16b** showed potent activity against promastigotes and axenic amastigotes of *L. amazonensis*, and higher




Fig. 2. Ultrastructural alterations in promastigotes of *Leishmania amazonensis* treated with **16b**, visualized by transmission electron microscopy. Control cells (A–C) and parasites treated with IC_{50} ($6.2 \mu M$) (D–F) for 24 h (A; D), 48 h (B; E) and 72 h (C; F). (n) nucleus; (m) mitochondrion; paraflagellar pocket; (*) lipid-storage bodies. Bars = $1 \mu m$.




Fig. 3. Morphological alterations in promastigotes of *Leishmania amazonensis* treated with **16b**, visualized by scanning electron microscopy. Control cells (A–C) and parasites treated with IC_{50} ($6.2 \mu M$) (D–F) for 24 h (A; D), 48 h (B; E) and 72 h (C; F). Bars = $5 \mu m$.

selectivity index than the other derivatives synthesized for both forms, it was submitted to studies for investigate their mechanism of protozoan cell death.

The treatment of *L. amazonensis* promastigotes with compound **16b** during 24 h caused ultrastructural alterations, mainly in mitochondria and plasma membrane. After 48 h of treatment, it was observed storage-lipid bodies, mitochondrial swelling and plasma membrane alterations. The treatment with 72 h showed alterations in flagellar pocket with vacuoles and mitochondrial swelling. These results initially demonstrated that in promastigotes the compound **16b** caused alterations in cell division cycle and, due to stress, it started a process of energy storage (storage-lipid bodies) [31], leading the cells to death through various factors (Fig. 2). For scanning electron microscopy (SEM) the treatment after 24, 48 and 72 h caused cell rounding and cell volume reduction (Fig. 3).

2.4. Biochemical assays

Leishmania amazonensis promastigotes were treated with compound **16b** at the concentrations corresponding to IC_{50} and IC_{90} , for

24 h, and loaded with 2',7'-dichlorodihydrofluorescein diacetate (H_2DCFDA), a probe that is permeable to the plasma membrane and chemically reduced in 2',7'-dichlorofluorescein (DCF) when in contact with reactive oxygen species (ROS), producing fluorescence. The parasites treated with positive control (0.5 and $4 \mu M$ of H_2O_2) showed a fluorescence increase of 45.9 and 230.8%, while treatment with **16b** with concentrations corresponding to IC_{50} and IC_{90} showed increase 81.9 and 184.8%. The parasites pre-incubated with *N*-acetyl-cysteine (NAC) and treatment with H_2O_2 (0.5 and $4 \mu M$) showed reversible effects, but the treatment with **16b** not showed such effects (Fig. 4A).

Additionally, the evaluation of lipid bodies was performed by using the probe Nile red. The positive control (H_2O_2) at concentrations of 0.5 and $4 \mu M$ showed an increase in fluorescence of 19% and 241.2%, respectively. The treatment with **16b** at concentrations corresponding to IC_{50} and IC_{90} showed an increase in fluorescence of 9% and 428.6%, respectively, confirming the increase of lipid-storage bodies. However, this accumulates of lipid-storage bodies is not related with the ROS generation, initially observed. The accumulation of lipid bodies is caused for cellular stress,




Fig. 4. Total ROS production using the fluorescent probe H_2DCFDA (A) and Nile Red accumulation (B) in promastigotes of *Leishmania amazonensis* treated with **16b** for 24 h. IC_{50} ($6.2 \mu M$); IC_{90} ($9.9 \mu M$). The data are expressed as relative fluorescence of at least three independent experiments. H_2O_2 was used as a positive control. Two-way ANOVA followed by Bonferroni post hoc test. * $p \leq 0.05$ compared to untreated parasites (control).

mitochondrial dysfunction and may be associated with apoptotic cell death [21,32] (Fig. 4B).

3. Conclusions

In this work, novel β -carboline-1,3,5-triazine hybrids containing different linkers between the β -carboline and 1,3,5-triazine units, chlorine and amino groups at 6- and 4-position of 1,3,5-triazine ring, and electron-donating and electron-withdrawing substituents at the 1-phenyl group of β -carboline nucleus have been synthesized and evaluated in promastigote and amastigote forms of *Leishmania amazonensis*. The assay results showed that the nature of substituents attached at β -carboline and 1,3,5-triazine moieties influenced the activity. The hybrid **9e**, containing the 3-nitrophenyl at C-1 of β -carboline was the most active among the compounds bearing chlorine atoms at 1,3,5-triazine ring, displaying potent activity for both promastigote and amastigote forms.

The presence of amino groups at 1,3,5-triazine nucleus led to loss of activity for almost all compounds, except for those bearing the isopropylamino group (**16a**, **16b**, **16e**, **17a** and **17c**). Compound **16b** containing the 4-methoxyphenyl at C-1 of β -carboline nucleus showed potent activity and low toxicity to amastigote and promastigote forms of *L. amazonensis*, being a promising candidate for antileishmanial agent.

Studies on mechanism of action showed that in promastigotes the compound **16b** caused alterations in cell division cycle and an increase of lipid-storage bodies, leading the cells to death through various factors. This accumulation of lipid bodies is caused of cellular stress, mitochondrial dysfunction and may be associated with apoptotic cell death.

In summary, from our results it was possible to obtain new hybrids β -carboline-1,3,5-triazine with remarkable antileishmanial activity, which can be considered as potential compounds for future studies in view to development of new antileishmanial agents.

4. Experimental section

4.1. General methods

All reagents were purchased from commercial suppliers. The reactions were monitored by thin layer chromatography conducted on Whatman TLC plates (Silica Gel 60 F₂₅₄). NMR spectra were recorded in a Varian spectrometer model Mercury plus BB at 300 MHz (for ¹H) and 75 MHz (for ¹³C), and in a Bruker spectrometer model Avance III HD at 500 MHz (for ¹H) and 125 MHz (for ¹³C), with TMS and deuterated solvents, dimethyl sulfoxide (DMSO-*d*₆) and chloroform (CDCl₃), as internal standard. Mass spectra (ESI/MS) were recorded on Thermoelectron Corporation Focus-DSQ II spectrometer. Melting points were determined in Microquímica apparatus model MQAPF-301 and are uncorrected.

The following chemicals were used in biological assay: Warren medium; fetal bovine serum (FBS); carbonyl cyanide *m*-chlorophenylhydrazone (CCCP), dimethylsulfoxide (DMSO), Roswell Park Memorial Institute Medium (RPMI 1640; Gibco 99 Invitrogen, Grand Island, NY, USA), 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), potassium sodium buffer; Nile red (Sigma); 2',7'-dichlorodihydrofluorescein diacetate (H₂DCFDA-ThermoFisher); sodium cacodylate (Electron Microscopy Scanning - EMS); glutaraldehyde 25% (EMS); potassium ferrocyanide; osmium tetroxide; EPON resin; acetone P.A.; uranyl acetate; lead citrate.

4.2. Chemistry

4.2.1. Synthesis of *L*-tryptophan methyl ester (**2**)

To a suspension of commercial *L*-tryptophan (**1**) (5.00 g,

24.5 mmol) in methanol (50 mL) was added dropwise concentrated sulfuric acid until complete solubilization. The reaction mixture was kept under reflux for 48 h. The solution was cooled and neutralized with a solution of 5% sodium carbonate, and extracted with ethyl acetate (4 × 30 mL). The organic phase was dried with anhydrous sodium sulfate and after filtration the solvent was removed in a rotary evaporator. The pure product was obtained in 91% yield.

4.2.2. Synthesis of *cis e trans* 1-(substituted-phenyl)-3-carbomethoxy-1,2,3,4-tetrahydro- β -carboline (**3a-e**)

To a solution of *L*-tryptophan methyl ester (**2**) (4.6 mmol) in dichloromethane (20 mL) was added 4.6 mmol of aldehyde [benzaldehyde (**a**), 4-methoxy-benzaldehyde (**b**), 4-fluoro-benzaldehyde (**c**), 2-chloro-benzaldehyde (**d**) and 3-nitro-benzaldehyde (**e**)] and trifluoroacetic acid (9.20 mmol). The reaction mixture was kept at room temperature and its progress monitored by TLC. After complete consumption of starting materials (48 h), the solvent was evaporated, and the crude product solubilized in ethyl acetate and neutralized with a solution of 5% sodium carbonate. The solution was extracted with ethyl acetate (3 × 30 mL). The organic phase was dried with anhydrous sodium sulfate, filtered and the solvent was removed in a rotary evaporator. The solid obtained was washed with methanol, providing a mixture of *cis* and *trans* 1-(substituted-phenyl)-3-carbomethoxy-tetrahydro- β -carboline (**3a-e**) in yields in the range 75–85%.

4.2.3. Synthesis of methyl 1-(substituted-phenyl)- β -carboline-3-carboxylates (**4a-e**)

To the mixture of *cis* and *trans* 1-(substituted-phenyl)-3-carbomethoxy-1,2,3,4-tetrahydro- β -carbolines **3a-e** (6.53 mmol) suspended in xylene (30 mL) was added 20 mmol of sulfur. The mixture was refluxed and the reaction progress monitored by TLC every 12 h. After complete consumption of starting materials (48 h), the solution was cooled and left on ice bath at 0 °C for approximately 1 h. The precipitate formed was filtered and washed with petroleum ether to afford the β -carbolines **4a-e** in yields in the range of 85–93%.

4.2.4. Synthesis of 1-(substituted-phenyl)- β -carboline-3-carbohydrazides (**5a-e**)

To a solution of compounds **4a-e** (3.31 mmol) in ethanol (30 mL) was added hydrazine hydrate 50% (66 mmol). The solution was kept under reflux and the reaction progress monitored by TLC every 12 h. After complete consumption of starting materials (48 h), the solution was cooled and left on ice bath at 0 °C for 1 h. The precipitate formed was filtered in vacuum and washed with ethanol to afford the compounds **5a-e** in yields in the range of 53–85%.

4.2.5. Synthesis of *N*-(2-aminoethyl)-1-(substituted-phenyl)- β -carboline-3-carboxamides (**6a-e**)

The compounds **4a-e** (1 mmol) were solubilized in 1 mL of ethylenediamine and the resulting solution was stirred at room temperature. The reaction progress was monitored by TLC every 8 h, and after complete consumption of starting materials (24 h), the solution was treated with 2 mL of distilled water and kept at 0 °C for approximately 1 h. The precipitates formed were filtered in vacuum and washed with distilled water to furnish the compounds **6a-e** in yields in the range of 60–90%.

4.2.6. Synthesis of *N*-(6-aminoethyl)-1-phenyl- β -carboline-3-carboxamide (**7a**)

To a solution of hexamethylenediamine (0.70 g) in chloroform (2 mL), under reflux, was added a solution of **4a** (0.3 mmol in 0.5 mL of methanol). The solution was kept under reflux, and the reaction

progress monitored by TLC every 12 h. After complete consumption of starting materials (36 h), the solution was cooled and treated with 2 mL of distilled water and the precipitate formed was filtered and washed with a mixture of water-ethanol (1:1). The compound **7a** was obtained in 70% yield.

4.2.7. Procedure for the preparation of β -carboline-4,6-dichloro-1,3,5-triazine derivatives (**8a-d**, **9a-d** and **10a**)

To a suspension of cyanuric chloride (0.2 mmol) in water-acetonitrile 1:1 (0.5 mL), at 0 °C, was added a suspension of **5a-d** (0.2 mmol), **6a-d** (0.2 mmol) or **7a** (0.2 mmol) in THF (3 mL). The pH was adjusted to 9–10 with sodium hydroxide 1 mol L⁻¹. The reaction mixture was stirred at 0 °C for 1 h and treated with distilled water (1 mL). The precipitates formed were filtered and washed with distilled water to afford compounds **8a-d**, **9a-d** or **10a** in yields in the range of 45–98%.

4.2.7.1. N'-(4,6-dichloro-1,3,5-triazin-2-yl)-1-phenyl- β -carboline-3-carbohydrazide (8a**).** Yellow crystals; Yield: 50%; M.p. > 350 °C (decomp.); ¹H NMR (300 MHz): δ ppm: 7.33 (t, J = 7.3, 1H, H-6), 7.56–7.74 (m, 5H, H-7, H-8, H-3', H-4', H-5'), 8.25 (d, J = 7.2, 2H, H-2', H-6'), 8.44 (d, J = 7.8, 1H, H-5), 8.87 (s, 1H, H-4), 10.98 (s, 1H, CO-NH), 11.98 (s, 1H, NH, H-9). ¹³C NMR (75 MHz): δ ppm: 112.8 (CH, C-8), 114.1 (CH, C-4), 120.4 (CH, C-6), 121.2 (C₀, C-4b), 122.1 (CH, C-5), 128.8 (3CH, C-2', C-4', C-6'), 129.0 (CH, C-3', C-5'), 129.1 (CH, C-7), 129.8 (C₀, C-4a), 134.5 (C₀, C-9a), 137.2 (C₀, C-1'), 138.8 (C₀, C-3), 141.0 (C₀, C-1), 141.6 (C₀, C-8a), 163.9 (C₀, C-2'''), 164.5 (C=O), 169.1 and 170.3 (C₀, C-4''', C-6'''); HRMS-ESI calcd for C₂₁H₁₄Cl₂N₇O [M+H]⁺ 450.0631, found: 450.0599, error 7.1 ppm.

4.2.7.2. N'-(4,6-dichloro-1,3,5-triazin-2-yl)-1-(4-methoxyphenyl)- β -carboline-3-carbohydrazide (8b**).** Yellow crystals; Yield: 98%; M.p. > 350 °C (decomp.); ¹H NMR (300 MHz): δ ppm: 3.90 (s, 3H, OCH₃), 7.20 (d, J = 8.9, 2H, H-3', H-5'), 7.32 (t, J = 7.5, 1H, H-6), 7.61 (t, J = 7.6, 1H, H-7), 7.72 (d, J = 8.2, 1H, H-8), 8.23 (d, J = 8.9, 2H, H-2', H-6'), 8.43 (d, J = 7.8, 1H, H-5), 8.83 (s, 1H, H-4), 10.89 (s, 1H, CO-NH), 11.94 (s, 1H, NH, H-9). ¹³C NMR (75 MHz): δ ppm: 55.4 (OCH₃), 112.8 (CH, C-8), 113.3 (CH, C-4), 114.1 (2CH, C-3', C-5'), 120.3 (CH, C-6), 121.2 (C₀, C-4b), 122.0 (CH, C-5), 130.4 (2CH, C-2', C-6'), 129.6 (CH, C-7), 129.5 (C₀, C-4a), 128.7 (C₀, C-9a), 134.0 (C₀, C-1'), 138.5 (C₀, C-3), 140.5 (C₀, C-1), 141.6 (C₀, C-8a), 160.0 (C₀, C-4'), 164.5 (C₀, C-2'''), 164.5 (C=O), 166.1 and 167.1 (C₀, C-4''', C-6'''); HRMS-ESI calcd for C₂₂H₁₆Cl₂N₇O₂ [M+H]⁺ 480.0737, found: 480.0731, error 1.2 ppm.

4.2.7.3. N'-(4,6-dichloro-1,3,5-triazin-2-yl)-1-(4-fluorophenyl)- β -carboline-3-carbohydrazide (8c**).** Yellow crystals; Yield: 47%; M.p. > 298 °C (decomp.); ¹H NMR (300 MHz): δ ppm: 7.32 (td, J = 7.5, 1.1, 1H, H-6), 7.47 (t, J = 8.9, 2H, H-3', H-5'), 7.61 (td, J = 7.6, 1.1, 1H, H-7), 7.71 (d, J = 8.2, 1H, H-8), 8.28 (dd, J = 8.9, 5.5, 2H, H-2', H-6'), 8.42 (d, J = 7.8, 1H, H-5), 8.79 (s, 1H, H-4), 11.53 (s, 1H, CO-NH), 11.94 (s, 1H, NH, H-9). ¹³C NMR (75 MHz): δ ppm: 112.7 (CH, C-8), 112.7 (CH, C-4), 115.5 and 115.8 (2 CH, C-3', C-5'), 120.3 (CH, C-6), 121.2 (C₀, C-4b), 122.1 (CH, C-5), 128.7 (CH, C-7), 130.3 (C₀, C-4a), 130.7 and 130.8 (2 CH, C-2', C-6'), 130.9 (C₀, C-9a), 133.8 (C₀, C-1'), 133.8 (C₀, C-3), 141.6 (C₀, C-1), 141.6 (C₀, C-8a), 161.1 (C₀, C-4'), 164.3 (C₀, C-2'''), 164.3 (C=O); HRMS-ESI calcd for C₂₁H₁₃Cl₂FN₇O [M+H]⁺ 468.0537, found: 468.0534, error 0.6 ppm.

4.2.7.4. N'-(4,6-dichloro-1,3,5-triazin-2-yl)-1-(2-chlorophenyl)- β -carboline-3-carbohydrazide (8d**).** Yellow crystals; Yield: 45%; M.p. > 345 °C (decomp.); ¹H NMR (300 MHz): δ ppm: 7.31 (m, 1H, H-6), 7.73 (m, 2H, H-7, H-8), 7.60 (m, 4H, H-3', H-4', H-5', H-6'), 8.43 (d, J = 8.0, 1H, H-5), 8.88 (s, 1H, H-4), 11.04 (s, 1H, CO-NH), 11.71 (s, 1H, NH, H-9). ¹³C NMR (75 MHz): δ ppm: 112.4 (CH, C-8), 114.6 (CH,

C-4), 120.2 (CH, C-6), 121.0 (C₀, C-4b), 122.3 (CH, C-5), 127.5 (CH, C-7), 128.8 (CH, C-5'), 129.8 (C₀, C-4a), 130.7 (C₀, C-2'), 132.2 (CH, C-3'), 132.3 (CH, C-6'), 132.6 (C₀, C-4'), 135.4 (C₀, C-1'), 136.3 (C₀, C-3), 136.4 (C₀, C-9a), 140.1 (C₀, C-1), 141.4 (C₀, C-8a); HRMS-ESI calcd for C₂₁H₁₃Cl₃N₇O [M+H]⁺ 484.0242, found: 484.0214, error 5.8 ppm.

4.2.7.5. N-{2-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]ethyl}-1-phenyl- β -carboline-3-carboxamide (9a**).** White crystals; Yield: 75%; M.p: 146–150 °C; ¹H NMR (500 MHz): δ ppm: 3.54 (m, 2H, H-2''), 3.60 (m, 2H, H-1''), 7.32 (ddd, J = 7.9, 7.0, 0.9, 1H, H-6), 7.56–7.70 (m, 5H, H-7, H-8, H-3', H-4', H-5'), 8.13 (dd, J = 8.2, 1.2, 2H, H-2', H-6'), 8.42 (d, J = 8.1, 1H, H-5), 8.83 (s, 1H, H-4), 8.87 (t, J = 6.2, CONH), 9.25 (t, J = 5.6, 1H, NH-C2''), 11.84 (s, 1H, NH, H-9). ¹³C NMR (125 MHz): δ ppm: 37.8 (CH₂, C-1''), 40.9 (CH₂, C-2''), 112.7 (CH, C-8), 113.1 (CH, C-4), 120.2 (CH, C-6), 121.2 (C₀, C-4b), 122.0 (CH, C-5), 128.6 (CH, C-4'), 128.7 (2CH, C-2', C-6'), 128.8 (CH, C-3', C-5'), 128.9 (CH, C-7), 129.8 (C₀, C-4a), 134.2 (C₀, C-9a), 137.5 (C₀, C-1'), 139.7 (C₀, C-3), 140.6 (C₀, C-1), 141.6 (C₀, C-8a), 165.3 (C₀, C-2'''), 165.5 (C=O), 168.4 and 169.4 (C₀, C-4''', C-6'''); HRMS-ESI calcd for C₂₃H₁₈Cl₂N₇O [M+H]⁺ 478.0944, found: 478.0946, error 0.4 ppm.

4.2.7.6. N-{2-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]ethyl}-1-(4-methoxyphenyl)- β -carboline-3-carboxamide (9b**).** White crystals; Yield: 87%; M.p: 194–196 °C; ¹H NMR (500 MHz): δ ppm: 3.54 (m, 2H, H-2''), 3.60 (m, 2H, H-1''), 3.89 (s, 3H, OCH₃), 7.19 (d, J = 8.9, 2H, H-3', H-5'), 7.30 (t, J = 7.9, 1H, H-6), 7.59 (ddd, J = 8.2, 7.1, 1.1, 1H, H-7), 7.69 (d, J = 8.2, 1H, H-8), 8.10 (d, J = 8.9, 2H, H-2', H-6'), 8.39 (d, J = 7.9, 1H, H-5), 8.77 (s, 1H, H-4), 8.86 (t, J = 6.1, CONH), 9.26 (t, J = 5.6, 1H, NH-C2''), 11.79 (s, 1H, NH, H-9). ¹³C NMR (125 MHz): δ ppm: 37.8 (CH₂, C-1''), 40.9 (CH₂, C-2''), 55.4 (OCH₃), 112.5 (CH, C-8), 112.7 (CH, C-4), 114.2 (2CH, H-3', H-5'), 120.1 (CH, C-6), 121.3 (C₀, C-4b), 122.0 (CH, C-5), 129.6 (C₀, C-4a), 128.5 (CH, C-7), 129.9 (C₀, C-9a), 130.1 (2CH, C-2', C-6'), 134.0 (C₀, C-1'), 139.5 (C₀, C-3), 140.5 (C₀, C-1), 141.5 (C₀, C-8a), 159.9 (C₀, C-4'), 165.3 (C₀, C-2'''), 165.5 (C=O), 168.4 and 169.4 (C₀, C-4''', C-6'''); HRMS-ESI calcd for C₂₄H₂₀Cl₂N₇O₂ [M+H]⁺ 508.1050, found: 508.1047, error 0.6 ppm.

4.2.7.7. N-{2-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]ethyl}-1-(4-fluorophenyl)- β -carboline-3-carboxamide (9c**).** White crystals; Yield: 65%; M.p: 153–157 °C; ¹H NMR (300 MHz): δ ppm: 3.54 (m, 2H, H-2''), 3.60 (m, 2H, H-1''), 3.89 (s, 3H, OCH₃), 7.19 (d, J = 8.9, 2H, H-3', H-5'), 7.30 (t, J = 7.9, 1H, H-6), 7.59 (ddd, J = 8.2, 7.1, 1.1, 1H, H-7), 7.69 (d, J = 8.2, 1H, H-8), 8.10 (d, J = 8.9, 2H, H-2', H-6'), 8.39 (d, J = 7.9, 1H, H-5), 8.77 (s, 1H, H-4), 8.86 (t, J = 6.1, CONH), 9.26 (t, J = 5.6, 1H, NH-C2''), 11.79 (s, 1H, NH, H-9). ¹³C NMR (75 MHz): δ ppm: 37.8 (CH₂, C-1''), 40.9 (CH₂, C-2''), 112.7 (CH, C-8), 113.2 (CH, C-4), 115.5 and 115.8 (2CH, H-3', H-5'), 120.3 (CH, C-6), 121.2 (C₀, C-4b), 122.1 (CH, C-5), 128.7 (C₀, C-4a), 130.0 (CH, C-7), 131.0 and 131.1 (2 CH, C-2', C-6'), 131.1 (C₀, C-9a), 133.8 (C₀, C-1'), 134.1 (C₀, C-3), 139.6 (C₀, C-1), 141.6 (C₀, C-8a), 165.2 (C₀, C-4'), 165.2 (C₀, C-2'''), 165.5 (C=O), 168.4 and 169.4 (C₀, C-4''', C-6'''); HRMS-ESI calcd for C₂₃H₁₇Cl₂FN₇O [M+H]⁺ 496.0850, found: 496.0849, error 0.2 ppm.

4.2.7.8. N-{2-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]ethyl}-1-(2-chlorophenyl)- β -carboline-3-carboxamide (9d**).** White crystals; Yield: 55%; M.p: 160–164 °C; ¹H NMR (300 MHz): δ ppm: 3.54 (m, 2H, H-2''), 3.60 (m, 2H, H-1''), 7.31 (dt, J = 7.9, 4.1, 4.1, 1H, H-6), 7.55–7.72 (m, 6H, H-7, H-8, H-3', H-4', H-5', H-6'), 8.43 (d, J = 7.9, 1H, H-5), 8.73 (t, J = 5.8, CONH), 8.91 (s, 1H, H-4), 9.21 (t, J = 5.2, 1H, NH-C2''), 11.67 (s, 1H, NH, H-9). ¹³C NMR (75 MHz): δ ppm: 37.7 (CH₂, C-1''), 40.9 (CH₂, C-2''), 112.4 (CH, C-8), 113.8 (CH, C-4), 120.1 (CH, C-6), 121.0 (C₀, C-4b), 122.2 (CH, C-5), 127.5 (CH, C-7), 128.7 (CH, C-5'), 128.9 (C₀, C-4a), 129.8 (C₀, C-2'), 130.6 (CH, C-3'), 132.1 (CH, C-6'), 132.7 (C₀, C-4'), 135.2 (C₀, C-1'), 136.4 (C₀, C-3), 139.2 (C₀, C-9a), 139.7 (C₀, C-1), 141.5 (C₀, C-8a), 165.1 (C₀, C-2'''), 165.5 (C=O),

168.3 and 169.3 (C₀, C-4''', C-6'''); HRMS-ESI calcd for C₂₃H₁₇Cl₃N₇O [M+H]⁺ 512.0555, found: 512.0555, error 0 ppm.

4.2.7.9. *N*-{6-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]hexyl}-1-phenyl-β-carboline-3-carboxamide (**10a**). White crystals; Yield: 74%; M.p: 101–102 °C; ¹H NMR (300 MHz): δ ppm: 1.36 (m, 4H, H-3'', H-4''), 1.51–1.62 (m, 4H, H-2'', H-5''), 3.24–3.29 (m, 2H, H-6''), 3.38–4.42 (m, 2H, H-1''), 7.32 (t, J = 7.1, 1H, H-6), 7.55–7.71 (m, 5H, H-7, H-8, H-3', H-4', H-5'), 8.16 (d, J = 7.0, 2H, H-2', H-6'), 8.41 (d, J = 7.9, 1H, H-5), 8.81 (s, 1H, H-4), 8.68 (t, J = 6.2, CONH), 9.14 (t, J = 5.5, 1H, NH-C2''). ¹³C NMR (75 MHz): δ ppm: 25.9 (CH₂, C-4''), 26.1 (CH₂, C-3''), 28.1 (CH₂, C-5''), 29.4 (CH₂, C-2''), 38.8 (CH₂, C-1''), 40.7 (CH₂, C-6''), 112.7 (CH, C-8), 112.9 (CH, C-4), 120.2 (CH, C-6), 121.2 (C₀, C-4b), 122.0 (CH, C-5), 128.6 (CH, C-4'), 128.7 (2CH, C-2', C-6'), 128.8 (CH, C-3', C-5'), 129.0 (CH, C-7), 129.9 (C₀, C-4a), 134.2 (C₀, C-9a), 137.5 (C₀, C-1'), 139.8 (C₀, C-3), 140.6 (C₀, C-1), 141.6 (C₀, C-8a), 165.1 (C=O, C-2''', C-4''', C-6'''), 167.6 (C=O); HRMS-ESI calcd for C₂₇H₂₆Cl₂N₇O [M+H]⁺ 534.1570, found: 534.1565, error 0.9 ppm.

4.2.8. Procedure for the preparation of β-carboline-4,6-dichloro-1,3,5-triazine derivative (**9e**)

A suspension of cyanuric chloride (0.2 mmol) and potassium carbonate (0.2 mmol) in anhydrous THF (1 mL) was stirred for 10 min at 0 °C, followed by the addition of **6c** (0.2 mmol) suspended in anhydrous THF (2 mL). The reaction mixture was stirred at 0 °C for 1 h, treated with 1 mL of distilled water and maintained in ice bath for 1 h. The precipitate formed was filtered and washed with distilled water providing **9e** in 93% yield.

4.2.8.1. *N*-{2-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]ethyl}-1-(3-nitrophenyl)-β-carboline-3-carboxamide (**9e**). Yellow crystals; Yield: 93%; M.p: 316–318 °C; ¹H NMR (300 MHz): δ ppm: 3.56 (m, 2H, H-2''), 3.63 (m, 2H, H-1''), 7.34 (td, J = 7.4; 1.2, 1H, H-6), 7.60–7.71 (m, 2H, H-7, H-8), 7.94 (t, J = 8.0, 1H, H-5'), 8.39–8.47 (m, 2H, H-5, H-4'), 8.56 (d, J = 7.8, 1H, H-6'), 8.83 (m, 1H, H-2'), 8.91 (s, 1H, H-4), 8.94 (m, 1H, NH-C2''), 9.25 (t, J = 5.2, 1H, CO-NH), 12.06 (s, 1H, NH, H-9). ¹³C NMR (75 MHz): δ ppm: 37.9 (CH₂, C-1''), 40.8 (CH₂, C-2''), 112.6 (CH, C-8), 114.1 (CH, C-4), 120.5 (CH, C-6), 121.2 (C₀, C-4b), 122.3 (CH, C-5), 123.5 (2CH, C-2', C-4'), 130.4 (C₀, C-4a), 129.0 (CH, C-7), 135.4 (C₀, C-9a), 130.4 (CH, C-5'), 138.2 (C₀, C-1'), 134.5 (CH, C-6'), 138.9 (C₀, C-3), 140.0 (C₀, C-1), 141.7 (C₀, C-8a), 148.3 (C₀, H-3'), 165.1 (C₀, C-2'''), 165.6 (C=O), 168.4 and 169.4 (C₀, C-4''', C-6'''); HRMS-ESI calcd for C₂₃H₁₇Cl₂N₈O₃ [M+H]⁺ 523.0795, found: 523.0791, error 0.8 ppm.

4.2.9. Procedure general for preparation of β-carboline-1,3,5-triazine derivatives **11a–15a**, **16a–d** and **17a–d**

To a suspension of cyanuric chloride (0.2 mmol) in water-acetonitrile 1:1 (0.5 mL), at 0 °C, was added **5a–d** (0.2 mmol) or **6a–d** (0.2 mmol) suspended in THF (3 mL). The pH was adjusted to 9–10 with sodium hydroxide 1 mol L⁻¹. The reaction mixture was stirred at 0 °C, for 1 h followed by addition of 10 equivalents of the appropriate amine. The mixture was kept at 70 °C, and the reaction progress monitored by TLC every 12 h. After complete consumption of starting materials (48 h), the solution was cooled and treated with 2 mL of distilled water. The precipitates formed were filtered, washed with distilled water and recrystallized with ethanol to afford compounds **11a–15a**, **16a–d** and **17a–d** in yields in range of 55–94%.

4.2.9.1. *N*-{2-[(4,6-dihydrazinyl-1,3,5-triazin-2-yl)amino]ethyl}-1-phenyl-β-carboline-3-carboxamide (**11a**). Yellow crystals; Yield: 86%; M.p: 186–189 °C; ¹H NMR (500 MHz): δ ppm: 3.42–3.57 (m, 4H, H-1'', H-2''), 4.12 (sl, 2H, NH₂), 6.88 (sl, 1H, NH-C2''), 7.31 (t,

J = 7.3, 1H, H-6), 7.58–7.70 (m, 5H, H-7, H-8, H-3', H-4', H-5'), 8.12 (d, J = 7.3, 2H, H-2', H-6'), 8.41 (d, J = 7.8, 1H, H-5), 8.83 (s, 1H, H-4), 8.80 (d, J = 5.3, CONH), 11.83 (s, 1H, NH, H-9). ¹³C NMR (75 MHz): δ ppm: 38.9 (CH₂, C-1''), 40.4 (CH₂, C-2''), 112.7 (CH, C-8), 113.0 (CH, C-4), 120.2 (CH, C-6), 121.2 (C₀, C-4b), 122.1 (CH, C-5), 128.6 (CH, C-4'), 128.7 (2CH, C-2', C-6'), 128.8 (CH, C-3', C-5'), 129.0 (CH, C-7), 129.9 (C₀, C-4a), 134.2 (C₀, C-9a), 137.5 (C₀, C-1'), 139.8 (C₀, C-3), 140.6 (C₀, C-1), 141.6 (C₀, C-8a), 165.1 (C=O, C-2''', C-4''', C-6'''), 167.6 (C=O); HRMS-ESI calcd for C₂₃H₂₄N₁₁O [M+H]⁺ 470.2160, found: 470.2160, error 0 ppm.

4.2.9.2. *N*-{2-[(4,6-bis(cyclohexylamino)-1,3,5-triazin-2-yl)amino]ethyl}-1-phenyl-β-carboline-3-carboxamide (**12a**). White crystals; Yield: 74%; M.p: 201–202 °C; ¹H NMR (500 MHz): δ ppm: 1.07–1.82 (m, 10H, H-2''', H-3''', H-4''', H-5''', H-6'''), 3.54–3.67 (m, 5H, H-1'', H-2'', H-1'''), 7.32 (m, 1H, H-6), 7.55–7.70 (m, 4H, H-7, H-3', H-4', H-5'), 7.69 (d, J = 8.2, 1H, H-8), 8.10 (sl, 2H, H-2', H-6'), 8.41 (d, J = 7.9, 1H, H-5), 8.82 (s, 1H, H-4), 8.73 (sl, CONH), 11.84 (s, 1H, NH, H-9). ¹³C NMR (125 MHz): δ ppm: 25.0 (2CH₂, C-3''', C-5'''), 25.4 (CH₂, C-4'''), 32.9 (2CH₂, C-2''', C-6'''), 39.4 (CH₂, C-1''), 41.4 (CH₂, C-2''), 48.6 (CH, C-1'''), 112.7 (CH, C-8), 112.9 (CH, C-4), 120.2 (CH, C-6), 121.2 (C₀, C-4b), 122.0 (CH, C-5), 128.7 (3CH, C-2', C-4', C-6'), 128.9 (3CH, C-3', C-5'), 129.9 (C₀, C-4a), 134.2 (C₀, C-9a), 137.5 (C₀, C-1'), 139.8 (C₀, C-3), 140.6 (C₀, C-1), 141.6 (C₀, C-8a), 165.0 (C₀, C-2'''), 165.0 (C=O), 166.0 (C₀, C-4''', C-6'''). HRMS-ESI calcd for C₃₅H₄₂N₉O [M+H]⁺ 604.3507, found: 604.3496, error 1.8 ppm.

4.2.9.3. *N*-{2-[(4,6-bis(benzylamino)-1,3,5-triazin-2-yl)amino]ethyl}-1-phenyl-β-carboline-3-carboxamide (**13a**). White crystals; Yield: 65%; M.p: 144–145 °C; ¹H NMR (300 MHz): δ ppm: 3.43–3.52 (m, 4H, H-1'', H-2''), 6.63–6.94 (m, 1H, NHC2'''), 7.21–7.35 (m, 6H, H-6, H-2''', H-3''', H-4''', H-5''', H-6'''), 7.53–7.71 (m, 5H, H-7, H-8, H-3', H-4', H-5'), 8.11 (d, J = 7.2, 2H, H-2', H-6'), 8.42 (d, J = 7.9, 1H, H-5), 8.84 (s, 1H, H-4), 8.71–8.74 (m, CONH), 11.84 (s, 1H, NH, H-9). ¹³C NMR (75 MHz): δ ppm: 39.7 (CH₂, C-1''), 40.2 (CH₂, C-2''), 43.0 and 43.3 (2CH₂, CH₂-Ph), 112.7 (CH, C-8), 113.0 (CH, C-4), 120.2 (CH, C-6), 121.3 (C₀, C-4b), 122.1 (CH, C-5), 126.4 (CH, C-2''', C-6'''), 126.9 (CH, C-4'''), 127.4 (CH, C-1'''), 128.0 (CH, C-3''', C-5'''), 128.7 (3CH, C-2', C-4', C-6'), 128.9 (C-3', C-5'), 129.0 (CH, C-7), 129.9 (C₀, C-4a), 134.2 (C₀, C-9a), 137.5 (C₀, C-1'), 139.8 (C₀, C-3), 140.7 (C₀, C-1), 141.6 (C₀, C-8a), 165.1 (C=O), 165.9 (C₀, C-2'''), 166.0 (C₀, C-4''', C-6'''); HRMS-ESI calcd for C₃₇H₃₄N₉O [M+H]⁺ 620.2881, found: 620.2859, error 3.5 ppm.

4.2.9.4. *N*-{2-[(4,6-bis(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)amino]ethyl}-1-phenyl-β-carboline-3-carboxamide (**14a**). Beige crystals; Yield: 55%; M.p: 158–160 °C; ¹H NMR (300 MHz): δ ppm: 2.00–2.27 (m, 10H, H-3''', H-5''', 2CH₃), 3.44–3.63 (m, 8H, H-1'', H-2'', H-2''', H-6'''), 6.88 (t, J = 5.1, 1H, NHC2'''), 7.32 (t, J = 7.3, 1H, H-6), 7.56–7.71 (m, 5H, H-7, H-8, H-3', H-4', H-5'), 8.07 (d, J = 6.7, 2H, H-2', H-6'), 8.41 (d, J = 7.8, 1H, H-5), 8.82 (s, 1H, H-4), 8.74 (t, J = 5.5, CONH), 11.84 (s, 1H, NH, H-9). ¹³C NMR (75 MHz): δ ppm: 39.4 (CH₂, C-1''), 40.1 (CH₂, C-2''), 42.4 (CH₂, C-2''', H-6'''), 45.7 (CH₃), 45.9 (CH₃), 54.3 (CH₂, C-3'''), 54.5 (CH₂, C-5'''), 112.7 (CH, C-8), 113.0 (CH, C-4), 120.2 (CH, C-6), 121.2 (C₀, C-4b), 122.0 (CH, C-5), 128.7 (3CH, C-2', C-4', C-6'), 128.8 (C-3', C-5'), 128.9 (CH, C-7), 129.9 (C₀, C-4a), 134.2 (C₀, C-9a), 137.5 (C₀, C-1'), 139.8 (C₀, C-3), 140.5 (C₀, C-1), 141.6 (C₀, C-8a), 164.6 (C₀, C-4''', C-6'''), 165.0 (C=O), 166.1 (C₀, C-2'''). HRMS-ESI calcd for C₃₃H₄₀N₁₁O [M+H]⁺ 606.3412, found: 606.3409, error 0.5 ppm.

4.2.9.5. *N*-{2-[(4,6-dimorpholino-1,3,5-triazin-2-yl)amino]ethyl}-1-phenyl-β-carboline-3-carboxamide (**15a**). Beige crystals; Yield: 84%; M.p: 193–194 °C; ¹H NMR (500 MHz): δ ppm: 3.50–3.60 (m, 12H, H-1'', H-2'', H-2''', H-3''', H-5''', H-6'''), 6.97 (t, J = 5.4, 1H, NHC2'''),

7.31 (t, J = 7.5, 1H, H-6), 7.55–7.64 (m, 4H, H-7, H-3', H-4', H-5'), 7.69 (d, J = 8.1, 1H, H-8), 8.10 (d, J = 7.2, 2H, H-2', H-6'), 8.41 (d, J = 7.8, 1H, H-5), 8.83 (s, 1H, H-4), 8.76 (t, J = 5.8, CONH), 11.83 (s, 1H, NH, H-9). ¹³C NMR (125 MHz): δ ppm: 39.4 (CH₂, C-1''), 40.1 (CH₂, C-2''), 43.1 (CH₂, C-2'''), 43.2 (CH₂, C-6'''), 66.0 (CH₂, C-3'''), 66.1 (CH₂, C-5'''), 112.7 (CH, C-8), 113.0 (CH, C-4), 120.2 (CH, C-6), 121.2 (C₀, C-4b), 122.0 (CH, C-5), 128.6 (CH, C-4'), 128.7 (2CH, C-2', C-6'), 128.8 (C-3', C-5'), 128.9 (CH, C-7), 129.9 (C₀, C-4a), 134.2 (C₀, C-9a), 137.5 (C₀, C-1'), 139.8 (C₀, C-3), 140.5 (C₀, C-1), 141.6 (C₀, C-8a), 164.7 (C₀, C-4'''), 165.0 (C=O), 166.0 (C₀, C-2'''). HRMS-ESI calcd for C₃₁H₃₄N₉O₃ [M+H]⁺ 580.2779, found: 580.2761, error 3.1 ppm.

4.2.9.6. N-[2-[(4,6-bis(isopropylamino)-1,3,5-triazin-2-yl)amino]ethyl]-1-phenyl-β-carboline-3-carboxamide (16a). White crystals; Yield: 94%; M.p: 200–201 °C; ¹H NMR (500 MHz): δ ppm: 1.05 (sl, 12H, CH₃), 3.45–3.55 (m, 4H, H-1'', H-2''), 4.02 (dq, J = 13.0, 6.7, 2H, CHCH₃), 6.06–6.64 (m, 3H, NH), 7.31 (t, J = 7.4, 1H, H-6), 7.55–7.70 (m, 5H, H-7, H-8, H-3', H-4', H-5'), 8.11 (d, J = 7.0, 2H, H-2', H-6'), 8.41 (d, J = 7.9, 1H, H-5), 8.82 (s, 1H, H-4), 8.74 (t, J = 5.6, CONH), 11.83 (s, 1H, NH, H-9). ¹³C NMR (125 MHz): δ ppm: 22.7 (CHCH₃), 39.8 (CH₂, C-1''), 39.9 (CH₂, C-2''), 40.1 (CHCH₃), 112.9 (CH, C-8), 112.7 (CH, C-4), 120.2 (CH, C-6), 121.2 (C₀, C-4b), 122.0 (CH, C-5), 128.6 (CH, C-4'), 128.7 (2CH, C-2', C-6'), 128.8 (2CH, C-3', C-5'), 128.9 (CH, C-7), 129.9 (C₀, C-4a), 134.2 (C₀, C-9a), 137.5 (C₀, C-1'), 139.8 (C₀, C-3), 140.6 (C₀, C-1), 141.6 (C₀, C-8a), 164.9 (C₀, C-2'''), 165.0 (2C₀, C-4''', C-6'''), 165.9 (C=O); HRMS-ESI calcd for C₂₉H₃₄N₉O [M+H]⁺ 524.2881, found: 524.2868, error 2.5 ppm.

4.2.9.7. N-[2-[(4,6-bis(isopropylamino)-1,3,5-triazin-2-yl)amino]ethyl]-1-(4-methoxyphenyl)-β-carboline-3-carboxamide (16b). White crystals; Yield: 75%; M.p: 262–264 °C; ¹H NMR (300 MHz): δ ppm: 1.05 (sl, 12H, CHCH₃), 3.55 (m, 4H, H-1'', H-2''), 3.89 (s, 3H, OCH₃), 4.03 (m, 2H, CHCH₃), 7.18 (d, J = 8.4, 2H, H-3', H-5'), 7.30 (t, J = 7.3, 1H, H-6), 7.58 (t, J = 7.3, 1H, H-7), 7.69 (m, 1H, H-8), 8.07 (d, J = 8.1, 2H, H-2', H-6'), 8.38 (d, J = 7.7, 1H, H-5), 8.77 (s, 1H, H-4), 8.73 (sl, CONH), 11.79 (s, 1H, NH, H-9). ¹³C NMR (75 MHz): δ ppm: 22.7 (CHCH₃), 38.6 (CH₂, C-1''), 41.2 (CHCH₃), 41.7 (CH₂, C-2''), 55.4 (OCH₃), 112.4 (CH, C-8), 112.7 (CH, C-4), 114.3 (2CH, H-3', H-5'), 120.2 (CH, C-6), 121.3 (C₀, C-4b), 122.0 (CH, C-5), 128.5 (C₀, C-9a), 129.7 (C₀, C-4a), 130.0 (CH, C-7), 130.1 (2CH, C-2', C-6'), 134.0 (C₀, C-1'), 139.6 (C₀, C-3), 140.5 (C₀, C-1), 141.5 (C₀, C-8a), 160.0 (C₀, C-4'), 165.0 (C₀, C-2'''), 165.1 (C=O), 166.0 (C₀, C-4''', C-6'''); HRMS-ESI calcd for C₃₀H₃₆N₉O₂ [M+H]⁺ 554.2986, found: 554.2990, error 0.7 ppm.

4.2.9.8. N-[2-[(4,6-bis(isopropylamino)-1,3,5-triazin-2-yl)amino]ethyl]-1-(4-fluorophenyl)-β-carboline-3-carboxamide (16c). White crystals; Yield: 48%; M.p: 190–195 °C; ¹H NMR (500 MHz): δ ppm: 1.05 (d, J = 6.90, 12H, CHCH₃), 3.30–3.60 (m, 4H, H-1'', H-2''), 4.03 (dd, J = 13.5; 6.8, 2H, CHCH₃), 7.46 (t, J = 8.8, 2H, H-3', H-5'), 7.32 (t, J = 7.5, 1H, H-6), 7.60 (t, J = 7.5, 1H, H-7), 7.68 (d, J = 8.2, 1H, H-8), 8.15 (sl, 2H, H-2', H-6'), 8.42 (d, J = 7.8, 1H, H-5), 8.73 (sl, CONH), 8.82 (s, 1H, H-4), 11.86 (sl, 1H, NH, H-9). ¹³C NMR (125 MHz): δ ppm: 22.6 (CHCH₃), 39.3 (CH₂, C-1''), 40.9 (CH₂, C-2''), 42.1 (CHCH₃), 112.6 (CH, C-8), 113.0 (CH, C-4), 115.6 (CH, H-3') 115.8 (CH, H-5'), 120.2 (CH, C-6), 121.2 (C₀, C-4b), 122.1 (CH, C-5), 128.7 (C₀, C-9a), 130.0 (C₀, C-4a), 130.8 (CH, C-2'), 130.9 (CH, C-6'), 133.9 (CH, C-7), 134.1 (C₀, C-1'), 139.5 (C₀, C-3), 139.7 (C₀, C-1), 141.6 (C₀, C-8a), 161.6 (C₀, C-4'), 163.6 (C=O), 164.9 (C₀, C-2''', C-4''', C-6'''); HRMS-ESI calcd for C₂₉H₃₃FN₉O [M+H]⁺ 542.2787, found: 542.2802, error 2.8 ppm.

4.2.9.9. N-[2-[(4,6-bis(isopropylamino)-1,3,5-triazin-2-yl)amino]ethyl]-1-(2-chlorophenyl)-β-carboline-3-carboxamide (16d). White crystals; Yield: 69%; M.p: 152–157 °C; ¹H NMR (300 MHz):

δ ppm: 1.05 (d, J = 4.3, 12H, CHCH₃), 3.38–3.52 (m, 4H, H-1'', H-2''), 4.01 (d, J = 6.0, 2H, CHCH₃), 7.31 (ddd, J = 7.9; 4.9; 3.1, 1H, H-6), 7.56–7.71 (m, 7H, H-7, H-8, H-3', H-4', H-5', H-6', NH), 8.42 (d, J = 7.8, 1H, H-5), 8.62 (sl, CONH), 8.90 (s, 1H, H-4), 11.66 (sl, 1H, NH, H-9). HRMS-ESI calcd for C₂₉H₃₃ClN₉O [M+H]⁺ 558.2491, found: 558.2486, error 0.9 ppm.

4.2.9.10. N'-[4,6-bis(isopropylamino)-1,3,5-triazin-2-yl]-1-phenyl-β-carboline-3-carbohydrazide (17a). White crystals; Yield: 49%; M.p: 204–206 °C; ¹H NMR (300 MHz): δ ppm: 1.12 (sl, 12H, CH₃), 4.05 (sl, 2H, CHCH₃), 6.58 (sl, 2H, NH), 7.33 (t, J = 7.2, 1H, H-6), 7.59–7.73 (m, 5H, H-7, H-8, H-3', H-4', H-5'), 8.25 (sl, H-2', H-6'), 8.45 (d, J = 7.6, 1H, H-5), 8.84 (s, 1H, H-4), 10.17 (s, CONH), 11.91 (s, 1H, NH, H-9). ¹³C NMR (75 MHz): δ ppm: 22.5 (CHCH₃), 40.7 (CHCH₃), 112.7 (CH, C-8), 113.4 (CH, C-4), 120.3 (CH, C-6), 121.2 (C₀, C-4b), 122.1 (CH, C-5), 128.7 (CH, C-4'), 128.8 (4CH, C-2', C-3', C-5', C-6'), 129.0 (CH, C-7), 129.8 (C₀, C-4a), 134.2 (C₀, C-9a), 137.4 (C₀, C-1'), 139.3 (C₀, C-3), 140.6 (C₀, C-1), 141.5 (C₀, C-8a), 164.0 (C=O), 165.0 (3C₀, C-2''', C-4''', C-6'''); HRMS-ESI calcd for C₂₇H₃₀N₉O [M+H]⁺ 496.2568, found: 496.2553, error 3.0 ppm.

4.2.9.11. N'-[4,6-bis(isopropylamino)-1,3,5-triazin-2-yl]-1-(4-methoxyphenyl)-β-carboline-3-carbohydrazide (17b). White crystals; Yield: 98%; M.p: 182–183 °C; ¹H NMR (500 MHz): δ ppm: 0.86–1.13 (m, 12H, CHCH₃), 3.90 (s, 3H, OCH₃), 4.04–4.09 (m, 2H, CHCH₃), 7.19 (d, J = 8.9, 2H, H-3', H-5'), 7.32 (t, J = 7.4, 1H, H-6), 7.60 (td, J = 7.7; 1.1, 1H, H-7), 7.71 (d, J = 8.2, 1H, H-8), 8.23 (d, J = 6.4, 2H, H-2', H-6'), 8.42 (d, J = 7.9, 1H, H-5), 8.79 (s, 1H, H-4), 10.15 (s, CONH), 11.85 (s, 1H, NH, H-9). ¹³C NMR (125 MHz): δ ppm: 22.5 (CHCH₃), 41.6 (CHCH₃), 55.4 (OCH₃), 112.7 (CH, C-8), 112.9 (CH, C-4), 114.1 (2CH, H-3', H-5'), 120.2 (CH, C-6), 121.3 (C₀, C-4b), 122.0 (CH, C-5), 129.6 (C₀, C-4a), 128.5 (CH, C-7), 129.8 (C₀, C-9a), 130.2 (2CH, C-2', C-6'), 134.0 (C₀, C-1'), 139.1 (C₀, C-3), 140.6 (C₀, C-1), 141.5 (C₀, C-8a), 160.0 (C₀, C-4'), 164.1 (C₀, C-2''', C-4''', C-6'''), 165.0 (C=O); HRMS-ESI calcd for C₂₈H₃₂N₉O₂ [M+H]⁺ 526.2673, found: 526.2639, error 6.5 ppm.

4.2.9.12. N'-[4,6-bis(isopropylamino)-1,3,5-triazin-2-yl]-1-(4-fluorophenyl)-β-carboline-3-carbohydrazide (17c). White crystals; Yield: 60%; M.p: 176–180 °C; ¹H NMR (300 MHz): δ ppm: 1.03–1.11 (m, 12H, CHCH₃), 4.04 (sl, 2H, CHCH₃), 6.57 (sl, 2H, NH), 7.32 (td, 7.2, 1.0, 1H, H-6), 7.46 (t, J = 8.9, 2H, H-3', H-5'), 7.61 (td, J = 7.7; 1.1, 1H, H-7), 7.71 (d, J = 8.2, 1H, H-8), 8.32 (sl, 2H, H-2', H-6'), 8.44 (d, J = 7.9, 1H, H-5), 8.84 (s, 1H, H-4), 10.22 (s, CONH), 11.92 (s, 1H, NH, H-9). ¹³C NMR (75 MHz): δ ppm: 22.6 (CHCH₃), 41.3 (CHCH₃), 112.7 (CH, C-8), 113.5 (CH, C-4), 115.5 and 115.7 (2CH, C-3', C-5'), 120.3 (CH, C-6), 121.2 (C₀, C-4b), 122.1 (CH, C-5), 128.7 (C₀, C-4a), 129.9 (CH, C-7), 131.1 and 131.2 (2CH, C-2', C-6'), 133.8 (C₀, C-9a), 134.1 (C₀, C-1'), 139.3 (C₀, C-3), 139.6 (C₀, C-1), 141.5 (C₀, C-8a), 161.0 (C₀, C-4'), 164.1 (C₀, C-2'''), 164.3 (C=O), 165.0 (2C₀, C-4''', C-6'''); HRMS-ESI calcd for C₂₇H₂₉FN₉O [M+H]⁺ 514.2474, found: 514.2460, error 2.7 ppm.

4.2.9.13. N'-[4,6-bis(isopropylamino)-1,3,5-triazin-2-yl]-1-(2-chlorophenyl)-β-carboline-3-carbohydrazide (17d). White crystals; Yield: 56%; M.p: 177–181 °C; ¹H NMR (300 MHz): δ ppm: 1.08 (sl, 12H, CHCH₃), 4.04 (sl, 2H, CHCH₃), 6.56 (sl, 1H, NH), 7.32 (ddd, J = 7.9; 4.8; 3.2, 1H, H-6), 7.59–7.74 (m, 4H, H-3', H-4', H-5', H-6'), 7.71–7.74 (m, 2H, H-7, H-8), 8.45 (d, J = 7.9, 1H, H-5), 8.91 (s, 1H, H-4), 9.91 (sl, CONH), 11.73 (s, 1H, NH, H-9). ¹³C NMR (75 MHz): δ ppm: 22.5 (CHCH₃), 41.2 (CHCH₃), 112.4 (CH, C-8), 114.2 (CH, C-4), 120.2 (CH, C-6), 121.1 (C₀, C-4b), 122.3 (CH, C-5), 127.5 (CH, C-7), 128.8 (CH, C-5'), 129.8 (C₀, C-4a), 130.7 (C₀, C-2'), 132.2 (CH, C-3'), 132.5 (CH, C-6'), 132.5 (C₀, C-4'), 135.3 (C₀, C-1'), 136.3 (C₀, C-3), 138.8 (C₀, C-9a), 139.8 (C₀, C-1), 141.4 (C₀, C-8a), 163.8 (C=O), 164.9 (2C₀, C-4''', C-

6'''), 167.3 (C₀, C-2'''); HRMS-ESI calcd for C₂₇H₂₉ClN₉O [M+H]⁺ 530.2178, found: 530.2162, error 3.0 ppm.

4.2.10. Procedure for the preparation of β -carboline-4,6-bis(isopropylamino)-1,3,5-triazine derivative (**16e**)

A suspension of cyanuric chloride (0.2 mmol) and potassium carbonate (0.2 mmol) in anhydrous THF (1 mL) was stirred for 10 min at 0 °C, followed by the addition of **6e** (0.2 mmol) suspended in anhydrous THF (2 mL). The reaction mixture was stirred at 0 °C for 1 h, followed by addition of 10 equivalents of isopropylamine. The mixture was kept at 70 °C, and the reaction progress monitored by TLC every 12 h. After complete consumption of starting materials (48 h), the solution was cooled and treated with 2 mL of distilled water. The precipitate formed was filtered and washed with distilled water, providing **16e** in 40% yield.

4.2.10.1. *N*-[2-[(4,6-bis(isopropylamino)-1,3,5-triazin-2-yl)amino]ethyl]-1-(3-nitrophenyl)- β -carboline-3-carboxamide (**16e**)

Yellow crystals; M.p. > 350 °C; Yield: 40%; ¹H NMR (300 MHz): δ ppm: 1.10 (dd, *J* = 7.8; 6.7, 12H, CHCH₃), 2.78 (t, *J* = 6.1, 2H, H-2''), 3.41 (q, *J* = 6.1, 2H, H-1''), 3.94–4.05 (m, 2H, CHCH₃), 7.34 (m, 1.2, 1H, H-6), 7.60–7.70 (m, 3H, H-7, H-8, NH), 7.94 (t, *J* = 8.0, 1H, H-5'), 8.39–8.46 (m, 2H, H-5, H-4'), 8.58 (d, *J* = 7.8, 1H, H-6'), 8.80–8.86 (m, 2H, H-2', NH), 8.91 (s, 1H, H-4). ¹³C NMR (75 MHz): δ ppm: 22.0 (CH₃CH), 41.2 (CH₂, C-1''), 41.6 (CH₂, C-2''), 42.0 (CHCH₃), 112.6 (CH, C-8), 113.9 (CH, C-4), 120.4 (CH, C-6), 121.2 (C₀, C-4b), 122.2 (CH, C-5), 123.5 (CH, C-2'), 123.6 (CH, C-4'), 129.0 (C₀, C-4a), 130.4 (CH, C-7), 130.4 (C₀, C-9a), 134.4 (CH, C-5'), 135.4 (C₀, C-1'), 138.1 (CH, C-6'), 139.0 (C₀, C-3), 140.1 (C₀, C-1), 141.7 (C₀, C-8a), 148.3 (C₀, H-3'), 164.5 (C₀, C-2'''), 164.5 (C=O), 164.7 (C₀, C-4''', C-6'''); HRMS-ESI calcd for C₂₉H₃₃N₁₀O₃ [M+H]⁺ 569.2732, found: 569.2702, error 5.3 ppm.

4.3. Antileishmanial activity

4.3.1. Parasites and cell culture

Leishmania amazonensis promastigotes were maintained at 25 °C in Warren medium and axenic amastigotes forms were maintained at 25 °C in Schneider's medium, supplemented with 10% FBS. J774-A1 macrophages were maintained at 37 °C under 5% CO₂ atmosphere in RPMI 1640 medium (pH 7.2) supplemented with 10% FBS.

4.3.2. Antiprotozoal activity

The effects of synthesized compounds were evaluated in promastigotes and axenic amastigotes forms of *L. amazonensis* in log phase of growth (48 h and 72 h, respectively) at concentration of 1 × 10⁻⁶ cells mL⁻¹. The inoculants were introduced into sterile 96-well micro plates containing increasing concentrations of compounds **8a-d**, **9a-e**, **10a-15a**, **16a-e** and **17a-d**. After incubation for 72 h at 25 °C and 32 °C for promastigotes and axenic amastigotes forms, was added 50 μ L of solution of XTT/PMS (0.5 and 0.3 mg mL⁻¹) in the absence of light. After 4 h, the absorbance was read in a spectrophotometer at 450 nm. The concentration that decreased 50% (IC₅₀) of the absorbance values compared with the negative control was determined by regression analysis of the data. To **16b** also was determined the concentration that decreased 90% (IC₉₀) of the absorbance values. Miltefosine was used as positive control.

4.3.3. Cytotoxicity assay

The cytotoxicity was evaluated in J774-A1 macrophages. To a suspension of macrophages in log phase growth (72 h) at concentration of 5 × 10⁻⁵ cells mL⁻¹ was cultured in RPMI 1640 medium supplemented with 10% FBS, were introduced into sterile 96-well micro plates and incubated for 24 h at 37 °C and 5% of CO₂

tension. After this period, the supernatant was removed and increasing concentrations of the substances were added. After 48 h of incubation under the same conditions mentioned above, the cells were washed with phosphate buffered saline 0.01 M and 50 μ L of MTT (2 mg mL⁻¹) was added to each well and incubated at absence of light at 25 °C. After 4 h, 150 μ L of DMSO was added in order to disrupt the cells and solubilize purple formazan crystals. The absorbance was read at 570 nm in microplate reader (Biotek Power Wave XS spectrofluorometer). The concentration that decreased 50% (CC₅₀) of the absorbance value compared with the negative control was determined by regression analysis of the data.

4.3.4. Electron microscopy

Promastigotes (1 × 10⁶ parasites/mL) were treated with IC₅₀ value of **16b** and incubated for 24, 48 and 72 h at 25 °C. The cells were fixed with 0.1 M cacodylate buffer and 2.5% of glutaraldehyde. For the ultrastructural analysis, promastigotes fixed were post-fixed with 1% OsO₄ and 0.8% potassium ferrocyanide in 0.1 M cacodylate buffer for 1 h. After that, the samples were dehydrated in acetone and included in EPON resin. Ultrathin sections of 60 nm were obtained and contrasted with uranyl acetate and lead citrate. The samples were observed in Microscopy Jeol JM 1400 TEM. For scanning electron microscopy (SEM), promastigotes were placed on a glass support with poly-L-lysine, dehydrated with ethanol and submitted at critical point (replacement of ethanol by CO₂). After that, the samples were metalized with gold and observed in FEI Quanta 250 SEM.

4.3.5. Oxidative stress analysis

Promastigotes (1 × 10⁶ parasites/mL) were pre-incubated or no with *N*-acetyl-cysteine (NAC) (10 μ M) for 3 h and after that, treated with IC₅₀ and IC₉₀ values of **16b** and incubated as previously described. After 24 h of incubation, the cells were washed in PBS and loaded with 10 μ M H₂DCFDA for 45 min. The fluorescence was determined in a Victor X3 spectrofluorometer at λ_{ex} of 488 nm and λ_{em} of 530 nm [33].

4.3.6. Storage-lipid bodies analysis

Promastigotes (1 × 10⁶ parasites/mL) were treated with IC₅₀ and IC₉₀ values of **16b** and incubated as previously described. After 24 h of incubation, the cells were washed in PBS and loaded with 10 μ g/mL Nile red for 30 min. The fluorescence was determined in a Victor X3 spectrofluorometer at λ_{ex} of 485 nm and λ_{em} of 535 nm [21].

4.3.7. Statistical analysis

The data shown in the tables and graphs are expressed as the mean \pm standard deviation of at least three independent experiments. The statistical analysis was realized using GraphPad Prism 6.0 software. The samples were analyzed using one-way analysis of variance (ANOVA), and the Tukey *post hoc* test was used to compare means when appropriate. Values of *p* of ≤ 0.05 were considered statistically significant.

Acknowledgments

This work was supported by Fundação Araucária (Brazil, PR, Process number 23.444 FA). We thank CAPES for fellowship (Baréa P) and to Complexo de Centrais de Apoio à Pesquisa of Universidade Estadual de Maringá (COMCAP-UEM) for the facilities.

Appendix A. Supplementary data

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.ejmech.2018.03.014>.

References

- [1] World Health Organization, Global Health Observatory (GHO) Data: Leishmaniasis: Situations and Trends, 2017 accessed 29 August 2017, http://www.who.int/gho/neglected_diseases/leishmaniasis/en/.
- [2] R. Reithinger, J. Dujardin, H. Louzir, C. Pirmez, B. Alexander, S. Brooker, Cutaneous Leishmaniasis, vol. 9, 2007, pp. 581–596. [https://doi.org/10.1016/S1473-3099\(07\)70209-8](https://doi.org/10.1016/S1473-3099(07)70209-8).
- [3] S.L. Croft, G.H. Coombs, Leishmaniasis- current chemotherapy and recent advances in the search for novel drugs, Trends Parasitol. 19 (2003) 502–508.
- [4] A. Ponte-Sucre, F. Gamarro, J. Dujardin, M.P. Barret, R. López-Vélez, R. García-Hernández, A.W. Pontain, R. Mwenchanya, B. Papadopolou, Drug resistance and treatment failure in leishmaniasis: a 21st century challenge, PLoS Neglected Trop. Dis. 12 (2017) 1–24. <https://doi.org/10.1371/journal.pntd.0006052>.
- [5] P. Mitropoulos, P. Konidas, M. Durkin-Konidas, New World cutaneous leishmaniasis: updated review of current and future diagnosis and treatment, J. Am. Acad. Dermatol. 63 (2010) 309–322.
- [6] F. Modabber, Leishmaniasis vaccines: past, present and future, Int. J. Antimicrob. Agents 36 (2010) 58–61. <https://doi.org/10.1016/j.ijantimicag.2010.06.024>.
- [7] H. Hussain, A. Al-Harrasi, A. Al-Rawahi, I.R. Green, S. Gibbons, Fruitful decade for antileishmanial compounds from 2002 to late 2011, Chem. Rev. 114 (2014) 10369–10428.
- [8] R. Cao, W. Peng, Z. Wang, A. Xu, β -carboline alkaloids: biochemical and pharmacological functions, Curr. Med. Chem. 14 (2007) 479–500.
- [9] A.E. Laine, C. Lood, A.M.P. Koskinen, Pharmacological importance of optically active tetrahydro- β -carbolines and synthetic approaches to create the C1 stereocenter, Molecules 19 (2014) 1544–1567.
- [10] S.S. Chauhan, S. Pandey, R. Shivahare, K. Ramalingam, S. Krishna, P. Vishwakarma, M.I. Siddiqi, S. Gupta, N. Goyal, P.M.S. Chauhan, Novel β -carboline–quinazolinone hybrid as an inhibitor of Leishmania donovani trypanothione reductase: synthesis, molecular docking and bioevaluation, Med. Chem. Commun. 6 (2015) 351–356.
- [11] V.M. Gohil, K.G. Brahmabhatt, P.M. Loiseau, K.K. Bhutani, Synthesis and anti-leishmanial activity of 1-aryl- β -carboline derivatives against Leishmania donovani, Bioorg. Med. Chem. Lett. 22 (2012) 3905–3907.
- [12] S. Manda, S.I. Khan, S.K. Jain, S. Mohammed, B. Tekwani, I.A. Khan, R.A. Vishwakarma, S.B. Bharate, Synthesis, antileishmanial and anti-trypanosomal activities of N-substituted tetrahydro- β -carbolines, Bioorg. Med. Chem. Lett. 24 (2014) 3247–3250.
- [13] A. Gellis, A. Dumètre, G. Lanzada, S. Hutter, E. Ollivier, P. Vanelle, N. Azas, Preparation and antiprotozoal evaluation of promising β -carboline alkaloids, N. Biomed. Pharmacother. 66 (2012) 339–347.
- [14] A. Kumar, S.B. Katiyar, S. Gupta, P.M.S. Chauhan, Synthesis of new substituted triazino tetrahydroisoquinolines and β -carbolines as novel antileishmanial agents, Eur. J. Med. Chem. 41 (2006) 106–113.
- [15] P. Ashok, S. Chander, A. Tejería, L. García-Calvo, R. Balana-Fouce, S. Murugesan, Synthesis and anti-leishmanial evaluation of 1-phenyl-2,3,4,9-tetrahydro-1H- β -carboline derivatives against Leishmania infantum, Eur. J. Med. Chem. 123 (2016) 814–821.
- [16] P. Ashok, S. Chander, L.M.C. Chow, I.L.K. Wong, R.P. Singh, P.N. Jha, M. Sankaranarayanan, Synthesis and in-vitro anti-leishmanial activity of (4-aryl)piperazin-1-yl(1-(thiophen-2-yl)-9H-pyrido[3,4-b]indol-3-yl)methanone derivatives, Bioorg. Chem. 70 (2017) 100–106.
- [17] H. Volpato, V.C. Desoti, J. Cogo, M.R. Panice, M.H. Sarragiotto, S.O. Silva, T. Ueda-Nakamura, C.V. Nakamura, The effects of N-butyl-1-(4-dimethylamino)phenyl-1,2,3,4-tetrahydro- β -carboline-3-carboxamide against Leishmania amazonensis are mediated by mitochondrial dysfunction, Evid. Based Complement. Alternat. Med. (2013) 1–7.
- [18] C.M.B.L. Silva, F.P. Garcia, J.H. da Silva Rodrigues, C.V. Nakamura, T. Ueda-Nakamura, E. Meyer, A.L.T. Gois Ruiz, M.A. Foglio, J.E. de Carvalho, W.F. da Costa, M.H. Sarragiotto, Synthesis, antitumor, antitrypanosomal and antileishmanial activities of benzo[4,5]canthin-6-ones bearing the N'-(substituted benzylidene)-carbohydrazide and N-alkylcarboxamide groups at C-2, Chem. Pharm. Bull. 60 (2012) 1372–1379.
- [19] L.T.D. Tonin, M.R. Panice, C.V. Nakamura, K.J.P. Rocha, A.O. Dos Santos, T. Ueda-Nakamura, W. Ferreira Da Costa, M.H. Sarragiotto, Antitrypanosomal and antileishmanial activities of novel N-alkyl-(1-phenylsubstituted- β -carboline)-3-carboxamides, Biomed. Pharmacother. 64 (2010) 386–389.
- [20] R.B. Pedroso, L.T.D. Tonin, T. Ueda-nakamura, B.P. Dias filho, M.H. Sarragiotto, C.V. Nakamura, β -carboline-3-carboxamide derivatives as promising antileishmanial agents, Ann. Trop. Med. Parasitol. 105 (2011) 549–557.
- [21] T.F. Stefanello, M.R. Panice, T. Ueda-Nakamura, M.H. Sarragiotto, R. Auzély-Velty, C.V. Nakamura, N-butyl-[1-(4-methoxy)phenyl-9H- β -carboline]-3-carboxamide prevents cytokinesis in Leishmania amazonensis, Antimicrob. Agents Chemother. 58 (2014) 7112–7120.
- [22] E.A. Mendes, V.C. Desoti, S.O. Silva, T. Ueda-nakamura, B.P. Dias Filho, S.F. Yamada-Ogatta, M.H. Sarragiotto MH, C.V. Nakamura, C5 induces different cell death pathways in promastigotes of Leishmania amazonensis, Chem. Biol. Interact. 256 (2016) 16–24.
- [23] P. Singla, V. Luxami, K. Paul, Triazine as a promising scaffold for its versatile biological behavior, Eur. J. Med. Chem. 102 (2015) 39–57.
- [24] N. Sunduru, A. Agarwal, S.B. Katiyar, Nishi, N. Goyal, S. Gupta, P.M.S. Chauhan, Synthesis of 2,4,6-trisubstituted pyrimidine and triazine heterocycles as antileishmanial agents, Bioorg. Med. Chem. 14 (2006) 7706–7715.
- [25] R.G. Booth, C.D. Selassie, C. Hansch, D.V. Santi, Quantitative structure-activity relationship of triazine-antifolate inhibition of Leishmania dihydrofolate reductase and cell growth, J. Med. Chem. 30 (1987) 1218–1224.
- [26] N. Sunduru, Nishi, S. Palne, P.M.S. Chauhan, S. Gupta, Synthesis and antileishmanial activity of novel 2,4,6-trisubstituted pyrimidines and 1,3,5-triazines, Eur. J. Med. Chem. 44 (2009) 2473–2481.
- [27] L. Gupta, N. Sunduru, A. Verma, S. Srivastava, S. Gupta, N. Goyal, P.M.S. Chauhan, Synthesis and biological evaluation of new [1,2,4]triazino [5,6-b]indol-3-ylthio-1,3,5-triazines and [1,2,4]triazino[5,6-b]indol-3-ylthio-pyrimidines against Leishmania donovani, Eur. J. Med. Chem. 45 (2010) 2359–2365.
- [28] K. Chauhan, M. Sharma, R. Shivahare, U. Debnath, S. Gupta, Y.S. Prabhakar, P.M.S. Chauhan, Discovery of triazine mimetics as potent antileishmanial agents, ACS Med. Chem. Lett. 4 (2013) 1108–1113.
- [29] G. Blotny, Recent applications of 2,4,6-trichloro-1,3,5-triazine and its derivatives in organic synthesis, Tetrahedron 62 (2006) 9507–9522.
- [30] V. Kaplun, J. Cogo, D.P. Sangi, T. Ueda-Nakamura, A.G. Corrêa, C.V. Nakamura, In vitro and in vivo activities of 2,3-diarylsbstituted quinoxaline derivatives in Leishmania amazonensis, Antimicrob. Agents Chemother. 60 (2016) 3433–3444. <http://doi:10.1128/AAC.02582-15>.
- [31] S.T. Macedo-Silva, J.A. Urbina, W. Souza, J.C.F. Rodrigues, In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania amazonensis, PLoS One (2013), e83247. <http://doi:10.1371/journal.pone.0083247>.
- [32] S.J. Lee, J. Zhang, A.M.K. Choi, H.P. Kim, Mitochondrial dysfunction induces formation lipid droplets as a generalized response to stress, Oxid. Med. Cell Longev. (2013) 327167. <https://doi.org/10.1155/2013/327167>.
- [33] A.K. Shukla, S. Patra, V.K. Dubey VK, Iridoid glucosides from Nyctanthes arborescens result in increased reactive oxygen species and cellular redox homeostasis imbalance in Leishmania parasite, Eur. J. Med. Chem. 54 (2012) 49–58. <https://doi.org/10.1016/j.ejmech.2012.04.034>.